Janux Therapeutics, Inc.

Trading Arrangements

During the three months ended December 31, 2025, no director or officer adopted orterminated any Rule 10b5-1 trading arrangement or any non-Rule 10b5-1 trading arrangement (as such terms are defined pursuant to Item 408(a) of Regulation S-K).

In addition, our officers (as defined in Rule 16a-1(f) under the Exchange Act) have entered into sell-to-cover arrangements adopted pursuant to Rule 10b5-1 authorizing the pre-arranged sale of shares to satisfy our tax withholding obligations arising exclusively from the vesting of restricted stock units. The amount of shares to be sold to satisfy our tax withholding obligations under these arrangements is dependent on future events which cannot be known at this time, including the future trading price of our shares. The expiration date relating to these arrangements is dependent on future events which cannot be known at this time, including the final vesting date of the applicable shares of restricted stock and the officer’s termination of service.

Appointment of Janeen Doyle as Interim Principal Accounting Officer

On February 25, 2026, in connection with Ms. Dobek’s temporary leave from the Company, the Board appointed Janeen Doyle, the Company’s Chief Corporate Business Development Officer, as the Company’s Interim Principal Accounting Officer (PAO), effective as of February 25, 2026.

Ms. Doyle, age 48, joined the Company in May 2025, is currently serving as our Chief Corporate Business Development Officer and in such capacity oversees the Company's accounting function. Prior to joining the Company, Ms. Doyle served in various roles at Flagship Pioneering from June 2024 to May 2025, most recently as Senior Partner and Senior Vice President. Prior to Flagship, Ms. Doyle spent over 15 years at Bristol Myers Squibb and Celgene, most recently serving Senior Vice President of Strategy and Business Development. Ms. Doyle holds a Bachelor of Science in biology from Moravian University and Masters in Business Administration from the University of Scranton.

There are no arrangements or understandings between Ms. Doyle and any other persons pursuant to which she was appointed as PAO, respectively. There are no family relationships between Ms. Doyle and any of the Company’s directors or executive officers and Ms. Doyle has no direct or indirect material interest in any transaction required to be disclosed by the Company pursuant to Item 404(a) of Regulation S-K.